Policy & Regulation
Gannex Pharma Co and Sagimet Biosciences complete patient enrolment in the ASC40 phase two NASH trial in China
19 November 2020 -

Gannex Pharma Co Ltd, a wholly owned company of Ascletis Pharma Inc (HKEX:1672) and United States-based Sagimet Biosciences Inc have completed patient enrolment in the ASC40 (TVB-2640) phase two NASH liver disease trial in China, it was reported on Wednesday.

The trial enrolled 30 patients in China and is part of the global phase two clinical program.

Sagimet Biosciences had revealed positive results on oral, once-daily dosing of NASH drug candidate ASC40 (TVB-2640) from its Phase two (FASCINATE-1) clinical trial in the United States. The preliminary data indicated that the product significantly decreased liver fat with a 61% responder rate in the 50mg group. The patients also revealed improvement in markers of liver function and fibrosis. In this randomised, placebo-controlled trial of 99 patients in the United States, clinicians assessed the safety and efficacy of the product for 12 weeks. The product is an orally bioavailable, first-in-class FASN inhibitor.